Immunotherapeutics, Volume 129 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Vaccines for the prophylaxis and treatment of HPV, Lung-targeted RNA-based therapeutics, Clostridium difficile: Current overview and future perspectives, Antivenoms for treatment of snake bites, Natural killer cell-based strategies for immunotherapy of cancer, Immunological insights of selectins in human disease mechanism, Current update, challenges, and future aspects of immunotherapeutics in non-small cell lung cancer, In silico interaction analysis of NEMO binding domain peptide on the NFkB protein, and much more.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. In silico tools and databases for designing cancer immunotherapy Anjali Dhall, Shipra Jain, Neelam Sharma, Leimarembi Devi Naorem, Dilraj Kaur, Sumeet Patiyal, and Gajendra P.S. Raghava2. Immunotherapeutic approaches for HPV-caused cervical cancerSeyed Amirreza Fatemi, Nadia Seifi, Shiva Rasekh, Sogand Amiri, Seyed Mohammad Iman Moezzi, Ashkan Bagheri, Shirin Fathi, and Manica Negahdaripour3. Natural killer cell-based strategies for immunotherapy of cancerOndrej Vanek, Barbora Kalouskov�, Celeste Abreu, Shiva Nejadebrahim and Ondrej Skorepa4. Noncoding RNAs as novel immunotherapeutic tools against cancer Maninder Kaur, Bhavneet Kaur, Monidipa Konar, and Sadhna Sharma5. Immunological insights of selectins in human disease mechanism Chandrabose Selvaraj, Rajaram Abhirami, Rajendran Vijayakumar, Faiz Abdulaziz Alfaiz, and Sanjeev Kumar Singh6. CoVaccine HTT adjuvant is superior to Freund's in eliciting ovine polyclonal antibodies against human tumor necrosis factor-alphaOwen R. Griffiths, John Landon, R. Keith Morris, Philip E. James, and Rachel A. Adams7. Clostridioides difficile: Current overview and future perspectives Joanna Giles and April Roberts8. A computational model revealing the immune-related hub genes and key pathways involved in rheumatoid arthritis (RA) Ambritha Balasundaram, S. Udhaya Kumar, and C. George Priya Doss9. Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach D. Thirumal Kumar, M.S. Shree Devi, S. Udhaya Kumar, Annie Sherlin, Aishwarya Mathew, M. Lakshmipriya, P. Sathiyarajeswaran, R. Gnanasambandan, R. Siva, R. Magesh, and C. George Priya Doss10. Immunotherapeutic interventions in Parkinson's disease: Focus on a-Synuclein Upasana Ganguly, Sukhpal Singh, Sasanka Chakrabarti, Adesh K. Saini, and Reena V. Saini11. Antivenom: An immunotherapy for the treatment of snakebite envenoming in sub-Saharan AfricaMender M. Mender, Fiona Bolton, Colin Berry, and Mark Young
Authors
Rossen Donev Head of Research, MicroPharm Limited, UK.
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
